AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against the combo.
Despite AbbVie’s assurances that divesting brazikumab would help level the competitive playing field after its $ 63 billion megamerger with Allergan, the proposed sale would not accomplish that goal, the groups told the Federal Trade Commission (FTC) in a letter (PDF) Tuesday.
Their rationale? Brazikumab’s buyer––AstraZeneca––is ill-positioned to bring the drug to market and does not have a strong enough pipeline to actively compete with AbbVie’s strong position in immunology. Moreover, AbbVie’s controversial use of “rebate walls” for its products, including for psoriasis med Skyrizi, would likely put any possible competitor, brazikumab included, in a tough position to compete against the more established med.
In late January, AstraZeneca opted to pick up brazikumab from Allergan as part of a three-drug sell-off to help clear up antitrust concerns raised during the FTC’s review of the $ 63 billion merger.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.